Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Updates and Advances in the Treatment of Metastatic HER2+ Breast Cancer

September 14th 2021

Dr Pegram and colleagues focus on key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Management of Early-Stage HER2-Positive Breast Cancer

September 14th 2021

In the second segment, Dr Pegram and colleagues discuss the clinical implications of the data from select trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Challenges and Unmet Needs in the Treatment of HER2-Positive Breast Cancer

September 14th 2021

In the first segment, Dr Pegram and colleagues highlight some of the challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.

Rapid Readout: Assessment of Tucatinib vs Placebo in the HER2CLIMB Study of Pretreated Patients with HER2+ Metastatic Breast Cancer

September 9th 2021

Expert oncologist Giuseppe Curigliano, MD, PhD, reflects on the updated results of the HER2CLIMB study evaluating tucatinib against placebo, each in combination with trastuzumab and capecitabine, in patients with pretreated HER2+ metastatic breast cancer.

Multidisciplinary Care for a Patient With Metastatic HER2+ Breast Cancer

September 8th 2021

An overview of optimal multidisciplinary care for a patient who presents with HER2+ metastatic breast cancer.

Challenges in the Multidisciplinary Management of Breast Cancer

September 8th 2021

Key opinion leaders highlight the challenges inherent in using multidisciplinary care to manage breast cancer, particularly when a patient is seen at multiple institutions.

New SITC Guidelines Provide First Recommendations for Immunotherapy in TNBC

September 2nd 2021

Following the integration of immunotherapy into the treatment paradigm of triple-negative breast cancer, a multidisciplinary panel of experts, brought together by the Society for Immunotherapy of Cancer, published the first clinical practice guidelines focused on navigating clinical decisions with immunotherapy in breast cancer.

Dr. Hurvitz on Outcomes With Sacituzumab Govitecan in TNBC

September 1st 2021

Sara A. Hurvitz, MD, discusses outcomes with sacituzumab govitecan-hziy in patients with metastatic triple-negative breast cancer.

Multidisciplinary Care in BC: How Best to Communicate Patient Information

September 1st 2021

Focusing on the value of electronic systems and tumor boards, experts detail how best to communicate across disciplines in the management of breast cancer.

Difference in Breast Cancer Outcomes With Multidisciplinary Care

September 1st 2021

Shared insight on how nuanced multidisciplinary care can positively impact outcomes when treating a patient with breast cancer.

Neoadjuvant Talazoparib Shows Activity in BRCA1/2+ Early HER2-Negative Breast Cancer

August 30th 2021

Jennifer K. Litton, MD, discusses the rationale for examining neoadjuvant talazoparib in patients with BRCA1/2-positive, early HER2-negative breast cancer, safety and efficacy results from NEOTALA, and next steps for research.

Roche Withdraws Atezolizumab PD-L1–Positive Metastatic TNBC Indication in the United States

August 30th 2021

Roche has made the voluntary decision to withdraw the indication for the use of atezolizumab plus chemotherapy in the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1.

Novel Combos Target Resistance Mechanisms in Advanced Hormone–Driven Breast Cancer

August 26th 2021

Acquired resistance to endocrine therapy has presented challenges for patients with hormone receptor–positive breast cancer.

Lenrolimab Plus Chemo Demonstrates Substantial Survival Benefit in Metastatic TNBC

August 26th 2021

Induction with lenrolimab resulted in an improvement in modified progression-free survival and modified overall survival in patients with metastatic triple-negative breast cancer.

Managing Breast Cancer: Collaboration Throughout the Treatment Journey

August 25th 2021

Comprehensive details on how multidisciplinary care is applied during a patient’s treatment journey, with a focus on pulmonology and critical care.

Managing Breast Cancer: Who’s Involved in Multidisciplinary Care?

August 25th 2021

Experts reflect on the importance of multidisciplinary care and outline the many disciplines involved in diagnosing and treating breast cancer.

Using Systemic Therapy to Treat HER2+ Breast Cancer

August 24th 2021

Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.

Emerging Therapies for HER2+ MBC

August 24th 2021

An overview of therapies under study in later-stage clinical trials to treat HER2-positive metastatic breast cancer.

Immunotherapy for HER2+ Breast Cancer

August 24th 2021

The rationale for incorporating checkpoint inhibitors into treatment regimens for HER2-positive breast cancer.

FDA Issues Warning on Utilization of Robotically-Assisted Surgical Devices in Mastectomy

August 24th 2021

The FDA issued an updated safety communication to remind the community that the safety and effectiveness of robotically-assisted surgical devices for use in mastectomy procedures or in the prevention or treatment of patients with breast cancer have not been established.

NEXT PAGE
PREVIOUS PAGE